TEASE-3 study: Positive interim data are reported for Stargardt drug

Ophthalmology Times EuropeOphthalmology Times Europe April 2024
Volume 20
Issue 3
Pages: 9 - 11

Gildeuretinol halts Stargardt disease progression, study results indicate

Hemoglobin molecule structure, rendered in pink and purple. Generative AI.  Image credit: ©Electro Unicorn – stock.adobe.com

The therapies currently in development for Stargardt disease work on four avenues of treatment, researchers say. Image credit: ©Electro Unicorn – stock.adobe.com

Alkeus Pharmaceuticals Inc recently announced the interim results of the TEASE-3 study of gildeuretinol (ALK-001) which showed that treatment halted progression of early-stage Stargardt disease for up to 6 years. Thus far, three teenagers enrolled in the TEASE-3 study have remained symptom- and progression-free during the course of their treatment. One patient has remained so for 2 years and two patients for 6 years.

This is a groundbreaking event in that Stargardt disease, which generally begins to cause visual symptoms during childhood but can begin occurring in adults, is an inherited genetic mutation that until now would progress unrelentingly to vision loss and blindness, due to buildup of material in the retina. Michael B. Gorin, MD, PhD, expressed encouragement by the results of the different TEASE trials.


Gildeuretinol is a novel molecule that the company describes as a specialised form of deuterated vitamin A that is designed to reduce the dimerisation of vitamin A without disturbing vision. In Stargardt disease, visual disruptions are caused by a mutation in the ABCA4 gene, as the resulting protein facilitates the accumulation of byproducts, leading to retinal damage.

In the TEASE-1 trial, gildeuretinol was initially tested in 50 patients with more advanced Stargardt disease and was found to slow the disease progression but not stop it, as in the TEASE-3 study of early-stage disease.

“This is what makes the results with early disease so dramatic,” Gorin stated. The dramatic preservation of vision in these younger patients highlights the need to consider the impact of therapies at different stages of the condition. Gildeuretinol met its prespecified primary efficacy end-point with a 21% reduction in the growth rate of retinal atrophic lesions
(P < .001; square root units, 28% effect for untransformed areas) against untreated patients. However, he noted, the teenagers in the TEASE-3 group had a much more impressive preservation of their retinal appearance and function.

The TEASE-2 trial is an ongoing, fully enrolled, randomised, triple-masked, placebo-controlled trial in which 80 patients with Stargardt disease are participating. According to a company news release, the top-line data are expected to be released in 2025.

The company noted that TEASE-3, the first clinical trial in early-stage Stargardt disease, is an open-label study of gildeuretinol. Participants had early signs of disease visible on retinal imaging but had not begun experiencing symptoms of vision loss. The patients underwent fundus autofluorescence imaging, and other outcome measures were used to assess the extent to which the drug affected disease progression. Year-over-year progression was assessed, as well as age-matched comparison to each participant’s untreated sibling with Stargardt disease and identical mutations.

The primary end-point of the TEASE-3 study is a measure of progression after the first 2 years of treatment. After the initial 2-year treatment, patients can continue to receive gildeuretinol for extended periods. TEASE-3 has enrolled a total of five patients to date with no signs of disease progression while on treatment. TEASE-3 is an open-label extension study. Gildeuretinol has received breakthrough therapy designation and orphan drug designation by the US FDA.

Vision loss in Stargardt disease

The theory behind vision loss in Stargardt disease lies in the mutation in the large ABCA4 gene, which encodes a molecule or protein that is considered a flippase that moves vitamin A from one cellular compartment to another for reprocessing and recycling, Gorin explained.

When there is a lack or insufficiency of protein activity, vitamin A accumulates in the cells and then forms a toxic product, seen as a fluorescent material on imaging. This accumulation then triggers the complement system that attacks the cells, resulting in epithelial cell and photoreceptor death and vision loss as the result of lipofuscin.

Considering this theory of visual loss, the therapies being developed are working on four avenues of treatment: reduce the amount of vitamin A taken up by photoreceptors to a safer level, provide modified vitamin A as gildeuretinol does by which the vitamin A requires more energy to react to itself and does not form toxic substances, pull lipofuscin out of the cells, and block the activation of complement in the cells of the eye to slow the triggering of cell death. The last therapeutic approach is already utilised in drugs to treat geographic atrophy associated with age-related macular degeneration.

Gene therapy is another approach whereby the mutated genes would be replaced or edited in the eye. Finally, investigators are developing approaches to reconstruct the outer retina and retinal pigment epithelium from induced progenitor stem cells grown from the patient but genetically corrected to have normal ABCA4 expression.

A challenging study

The TEASE-3 study was not a typical trial that enrolled affected patients and was supported by the FDA. Gorin recounted the great deal of discussion that went into study design. The first three children included, two of whom were his patients, were asymptomatic.

“This was a unique situation and opportunity in which investigators were approached by a family with an older child who had been diagnosed with Stargardt disease. When the trial started, the family sought treatment for the affected child but also for a younger, unaffected child who genetically had a one in four risk of developing Stargardt disease,” he said.

He described working through considerable discussions among the investigators and parents to address the ethical issues; specifically, is it ethical to have an asymptomatic child undergo molecular genetic testing without having a potential therapy? “We are well aware of the emotional impact on the child and parents when genetic testing robs the child of innocence with no expectation of a means to slow or halt the disease,” Gorin commented.

He added, “We also considered the issue of potential survivor guilt if we offered treatment to the younger person but withheld treatment [from] their older sibling, who had already experienced vision loss.”

In response to this, the investigators created the small trial, the TEASE-3 study, that allowed younger, asymptomatic patients from these highly motivated families to proceed with molecular genetic testing with the expectation that they would receive gildeuretinol if they had the same mutations as found in their older, affected siblings.

Another problem with such a study was the small number of participants and the ability to draw conclusions from the small body of data collected. Gorin explained that they had good clinical data from the siblings who were older than the younger ones by a few years. “We knew that within a few years the younger children would catch up in age to the point at which the older siblings were first diagnosed with Stargardt disease and had experienced measurable vision loss before receiving the medication as well. We would have comparative data that would be age-matched for a sibling,” he explained.

While this is not a trial design approved by the FDA, in this scenario it was the investigators’ best shot because they would know that the siblings had the same genetic mutation, lived in the same environment, had the same diet, and would most likely be very similar in other ways. Clinical data from their own patients and published studies had shown that disease severity (other than visual acuity) and patterns of retinal damage were very similar among siblings at comparable ages. Because of these factors, the investigators thought this was a reasonable strategy to study a rare disease.

The investigators knew, based on both the theory of how the drug worked and how the mutation in the ABC4A gene led to cell death, that it would be far better to treat patients with early disease before the cells died in order to preserve visual function, Gorin said.

Most patients, over 90%, have mutations in the ABCA4 gene, but as many as 12 other affected genes have been identified that can give rise to a phenotype that is similar to that of Stargardt disease. There are also multiple mutations that have been identified in ABCA4, which is a huge gene with 52 exons. And to further complicate the clinical picture, these mutations in the ABCA4 gene can give rise to different clinical appearances in a cone/rod dystrophy; those patients were not included in the TEASE trials.

Michael B. Gorin, MD, PhD | E: gorin@jsei.ucla.edu

Dr Gorin is from the Department of Ophthalmology and Department of Human Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).
He reported no financial interest in this subject matter and is not expressing the views of UCLA.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.